<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2411585553-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2411585553-430x241.jpg"/></p>
<p>安进正在收购总部位于英国的生物技术公司 Dark Blue Therapeutics，收购金额高达 8.4 亿美元。图片来源：Piotr Swat via ShutterStock.com。</p>
<p>安进已同意以高达 8.4 亿美元的价格收购总部位于英国的生物技术公司 Dark Blue Therapeutics，这标志着 2026 年的首笔制药收购。</p>
<p>通过此次交易，安进将获得 Dark Blue 的肿瘤学资产管线，包括 DBT 3757，这是一种针对髓系/淋巴系白血病易位 1 和 3（MLLT1/3）的研究性蛋白降解剂。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM: Agenus Inc 的 Botensilimab</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM: Amgen Inc 的 Tarlatamab</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现有效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>目前正在进行研究性新药（IND）启用研究，DBT 3757 正在开发用于急性髓系白血病（AML）的治疗，前期临床工作已经突显了其抗癌潜力。</p>
<p>根据 Dark Blue 的说法，该疗法与市场上已上市治疗的差异机制，以及其增强 AML 缓解持久性的潜力，为该药物的进一步开发提供了合理依据，可能作为单药治疗或与其他 AML 治疗选项联合使用。</p>
<p>安进研发执行副总裁 Jay Bradner 指出，此次收购将有助于公司 “早期投资新兴药物” 的战略，这些药物利用新型治疗靶点。</p>
<p>花旗分析师对此表示赞同，指出：“Dark Blue 的研究机构与安进的整合预计将进一步推动早期肿瘤学管线的实力。”</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>由 GlobalData 提供</p>
<p>了解更多关于战略情报</p>
<p>在此次合并后，预计 Dark Blue Therapeutics 将整合到安进现有的研究部门中。</p>
<h2>安进加大交易策略</h2>
<p>安进收购 Dark Blue Therapeutics 标志着这家总部位于加利福尼亚的制药公司自 2023 年以 278 亿美元收购生物制药公司 Horizon Therapeutics 以来的首次并购活动。这结束了安进的交易干旱期，该公司在 2024 年分别签署了一项许可和开发协议，而在 2025 年没有获得此类交易的批准。</p>
<p>安进在 2026 年似乎处于交易的前沿。在宣布收购 Dark Blue 的一天后，安进透露已与 DISCO Pharmaceuticals 签署了一项价值高达 6.18 亿美元的肿瘤学许可协议。</p>
<p>除了在肿瘤学方面的动作，安进还在关注肥胖领域，这是 礼来 和 诺和诺德 通过各自的胰高血糖素样肽-1 受体激动剂（GLP-1RAs）实现高药品销售的领域。</p>
<p>安进有自己的研究性 GLP-1 激动剂和葡萄糖依赖性胰岛素促分泌多肽受体（GIP）拮抗剂，名为 maridebart carfraglutide，也称为 MariTide。</p>
<p>尽管 GlobalData 分析师和关键意见领袖之前对该疗法抱有 很高的期望，称其在肥胖领域可能是一个 “游戏规则改变者”，但关于该药物可能 降低骨密度 的担忧已被提出。然而，安进对此进行了反驳，表示公司 “没有看到 MariTide 的使用与骨矿密度变化之间的关联”。</p>
<p>GlobalData 是 <em>Pharmaceutical Technology</em> 的母公司。</p>
<p>尽管发展道路坎坷，安进正在推进 MariTide 的后期开发计划。</p>
<p>根据花旗分析师的说法，安进的肥胖管线将 “在叙述中保持关键地位”。</p>

安进

<p>安进正在以高达 8.4 亿美元收购总部位于英国的生物技术公司 Dark Blue Therapeutics，这标志着 2026 年的首次制药行业收购。这项收购将增强安进的肿瘤学产品线，特别是针对急性髓性白血病的研究药物 DBT 3757。分析师认为，整合 Dark Blue 的研究可能会加强安进在早期肿瘤学方面的努力。在达成此交易后，安进还与 DISCO Pharmaceuticals 签署了一项价值 6.18 亿美元的肿瘤学许可协议，显示出在一段时间的停滞后，安进重新关注交易活动</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2411585553-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2411585553-430x241.jpg"/></p>
<p>Amgen is acquiring UK-based biotech Dark Blue Therapeutics in a buyout worth up to $840m. Image credit: Piotr Swat via ShutterStock.com.</p>
<div class="lb-trans"><p>安进正在收购总部位于英国的生物技术公司 Dark Blue Therapeutics，收购金额高达 8.4 亿美元。图片来源：Piotr Swat via ShutterStock.com。</p>
</div><p>Amgen has agreed to acquire UK-based biotech Dark Blue Therapeutics for up to $840m, making it the first pharma takeover of 2026.</p>
<div class="lb-trans"><p>安进已同意以高达 8.4 亿美元的价格收购总部位于英国的生物技术公司 Dark Blue Therapeutics，这标志着 2026 年的首笔制药收购。</p>
</div><p>Through this transaction, Amgen will gain access to Dark Blue’s pipeline of oncology assets – including DBT 3757, an investigational myeloid/lymphoid leukaemia translocation 1 and 3 (MLLT1/3)-targeted protein degrader.</p>
<div class="lb-trans"><p>通过此次交易，安进将获得 Dark Blue 的肿瘤学资产管线，包括 DBT 3757，这是一种针对髓系/淋巴系白血病易位 1 和 3（MLLT1/3）的研究性蛋白降解剂。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: Agenus Inc's Botensilimab</h4>
<div class="lb-trans"><h4>NPVM: Agenus Inc 的 Botensilimab</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: Amgen Inc's Tarlatamab</h4>
<div class="lb-trans"><h4>NPVM: Amgen Inc 的 Tarlatamab</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现有效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>Currently in investigational new drug (IND)-enabling studies, DBT 3757 is being developed for the treatment of acute myeloid leukaemia (AML), with preclinical work having already highlighted its anticancer potential.</p>
<div class="lb-trans"><p>目前正在进行研究性新药（IND）启用研究，DBT 3757 正在开发用于急性髓系白血病（AML）的治疗，前期临床工作已经突显了其抗癌潜力。</p>
</div><p>According to Dark Blue, the therapy’s differential mechanism to marketed treatments, as well as its potential to boost the durability of AML remission, builds rationale for the drug’s further development, which may be used both as a monotherapy and in combination with other AML treatment options.</p>
<div class="lb-trans"><p>根据 Dark Blue 的说法，该疗法与市场上已上市治疗的差异机制，以及其增强 AML 缓解持久性的潜力，为该药物的进一步开发提供了合理依据，可能作为单药治疗或与其他 AML 治疗选项联合使用。</p>
</div><p>Amgen’s executive VP of R&amp;D, Jay Bradner, noted that the acquisition would assist the company’s strategy of “investing early into rising medicines” that harness novel therapeutic targets.</p>
<div class="lb-trans"><p>安进研发执行副总裁 Jay Bradner 指出，此次收购将有助于公司 “早期投资新兴药物” 的战略，这些药物利用新型治疗靶点。</p>
</div><p>Citi analysts echoed this sentiment, noting: “The anticipated integration of Dark Blue’s research organisation into Amgen could further drive early oncology pipeline strength.”</p>
<div class="lb-trans"><p>花旗分析师对此表示赞同，指出：“Dark Blue 的研究机构与安进的整合预计将进一步推动早期肿瘤学管线的实力。”</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>Following this merger, Dark Blue Therapeutics is anticipated to integrate into Amgen’s existing research division.</p>
<div class="lb-trans"><p>在此次合并后，预计 Dark Blue Therapeutics 将整合到安进现有的研究部门中。</p>
</div><h2>Amgen ramps up dealmaking strategy</h2>
<div class="lb-trans"><h2>安进加大交易策略</h2>
</div><p>Amgen’s acquisition of Dark Blue Therapeutics marks the first M&amp;A activity the California-based pharma has engaged in since its $27.8bn acquisition of biopharmaceutical company Horizon Therapeutics in 2023.  This puts an end to a deal drought for Amgen, which saw the company sign one licensing and development agreement, respectively, in 2024, with no deals of this nature getting the green light in 2025.</p>
<div class="lb-trans"><p>安进收购 Dark Blue Therapeutics 标志着这家总部位于加利福尼亚的制药公司自 2023 年以 278 亿美元收购生物制药公司 Horizon Therapeutics 以来的首次并购活动。这结束了安进的交易干旱期，该公司在 2024 年分别签署了一项许可和开发协议，而在 2025 年没有获得此类交易的批准。</p>
</div><p>Amgen appears to be on the dealmaking front foot in 2026. A day after announcing the Dark Blue takeover, Amgen revealed it had signed an oncology licensing deal with DISCO Pharmaceuticals worth up to $618m.</p>
<div class="lb-trans"><p>安进在 2026 年似乎处于交易的前沿。在宣布收购 Dark Blue 的一天后，安进透露已与 DISCO Pharmaceuticals 签署了一项价值高达 6.18 亿美元的肿瘤学许可协议。</p>
</div><p>Alongside its movements in oncology, Amgen is eyeing entry into the obesity segment, an area where Eli Lilly and Novo Nordisk have recorded high drug sales through their respective glucagon-like peptide-1 receptor agonists (GLP-1RAs).</p>
<div class="lb-trans"><p>除了在肿瘤学方面的动作，安进还在关注肥胖领域，这是 礼来 和 诺和诺德 通过各自的胰高血糖素样肽-1 受体激动剂（GLP-1RAs）实现高药品销售的领域。</p>
</div><p>Amgen has its own investigational GLP-1 agonist and glucose-dependent insulinotropic polypeptide receptor (GIP) antagonist called maridebart carfraglutide – otherwise known as MariTide.</p>
<div class="lb-trans"><p>安进有自己的研究性 GLP-1 激动剂和葡萄糖依赖性胰岛素促分泌多肽受体（GIP）拮抗剂，名为 maridebart carfraglutide，也称为 MariTide。</p>
</div><p>While GlobalData analysts and key opinion leaders previously had high hopes for the therapy, calling it a potential “game changer” within the obesity space, concerns around the drug’s potential to diminish bone density have been raised. However, Amgen has refuted these claims, stating that the company “does not see an association between the administration of MariTide and bone mineral density changes”.</p>
<div class="lb-trans"><p>尽管 GlobalData 分析师和关键意见领袖之前对该疗法抱有 很高的期望，称其在肥胖领域可能是一个 “游戏规则改变者”，但关于该药物可能 降低骨密度 的担忧已被提出。然而，安进对此进行了反驳，表示公司 “没有看到 MariTide 的使用与骨矿密度变化之间的关联”。</p>
</div><p>GlobalData is the parent company of <em>Pharmaceutical Technology</em>.</p>
<div class="lb-trans"><p>GlobalData 是 <em>Pharmaceutical Technology</em> 的母公司。</p>
</div><p>Despite its rocky development path, Amgen is advancing MariTide’s late-stage development programme.</p>
<div class="lb-trans"><p>尽管发展道路坎坷，安进正在推进 MariTide 的后期开发计划。</p>
</div><p>According to Citi analysts, Amgen’s obesity pipeline will “remain key to the narrative”.</p>
<div class="lb-trans"><p>根据花旗分析师的说法，安进的肥胖管线将 “在叙述中保持关键地位”。</p>
</div>

安进以 8.4 亿美元收购 Dark Blue Therapeutics，达成肿瘤领域的交易